Home Stock

Stock Research: Chugai Pharmaceutical

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Chugai Pharmaceutical

TYO:4519 JP3519400000
62
  • Value
    49
  • Growth
    67
  • Safety
    Safety
    84
  • Combined
    37
  • Sentiment
    97
  • 360° View
    360° View
    62
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Chugai Pharmaceutical Co Ltd is a Japan-based company that researches, develops, manufactures, and sells pharmaceutical products. The company operates in the pharmaceutical industry, with products for treating cancer, kidney diseases, and other conditions. It operates in Japan, Switzerland, the United Kingdom, Germany, France, China, Singapore, Korea, and the United States. In the last fiscal year, the company had a market cap of $76,700 million, profits of $5,298 million, and revenue of $7,448 million with 7778 employees.

more
Strongest Rank Price vs. Earnings (P/E)
Weakest Rank Liquidity
Country Switzerland
Industry Pharmaceuticals
Size Large
Website chugai-pharm.co.jp
Index
TOPIX 100
Nikkei 225
Renewables Users
Chugai Pharmaceutical stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
49 20 20 35
Growth
67 47 37 23
Safety
Safety
84 80 84 78
Sentiment
97 82 70 58
360° View
360° View
62 42 51 41
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
30 35 63 37
Opinions Change
74 77 60 50
Pro Holdings
n/a 98 60 96
Market Pulse
76 50 56 24
Sentiment
97 82 70 58
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
49 20 20 35
Growth
67 47 37 23
Safety Safety
84 80 84 78
Combined
37 47 39 45
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
30 9 11 24
Price vs. Earnings (P/E)
24 28 33 60
Price vs. Book (P/B)
27 15 14 18
Dividend Yield
75 49 49 70
Value
49 20 20 35
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
49 29 13 33
Profit Growth
64 37 26 69
Capital Growth
64 47 42 48
Stock Returns
59 82 95 15
Growth
67 47 37 23
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
60 60 87 80
Refinancing
51 21 33 29
Liquidity
100 100 100 98
Safety Safety
84 80 84 78

Similar Stocks

Discover high‑ranked alternatives to Chugai Pharmaceutical and broaden your portfolio horizons.

Krka

LJU:KRKG
Country: Slovenia
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Bachem

SWX:BANB
Country: Switzerland
Industry: Life Sciences Tools & Services
Size: Medium
Full Stock Analysis

Swatch

VTX:UHR
Country: Switzerland
Industry: Apparel, Accessories, Luxury
Size: X-Large
Full Stock Analysis

Ipsen

PAR:IPN
Country: France
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Frequently Asked
Questions

The value case is weak (expensive and low Growth Rank), but sentiment is strong and financing is safe. This scenario may indicate future growth not yet in current financials. This is a speculative choice for investors with a high-risk appetite who are betting on the positive sentiment and safe financing to sustain a long-term turnaround.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews